Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.
DELIVER
An International, Double-blind, Randomised, Placebo-Controlled Phase III Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)
2 other identifiers
interventional
6,263
20 countries
348
Brief Summary
This is an international, multicentre, parallel-group, event-driven, randomised, double-blind, placebo-controlled study in HFpEF patients, evaluating the effect of dapagliflozin 10 mg versus placebo, given once daily in addition to background regional standard of care therapy, including treatments to control co-morbidities, in reducing the composite of CV death or heart failure events.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Aug 2018
Typical duration for phase_3
348 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 2, 2018
CompletedFirst Posted
Study publicly available on registry
August 7, 2018
CompletedStudy Start
First participant enrolled
August 27, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 27, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
March 27, 2022
CompletedResults Posted
Study results publicly available
July 11, 2023
CompletedJuly 11, 2023
July 1, 2023
3.6 years
August 2, 2018
March 9, 2023
July 10, 2023
Conditions
Outcome Measures
Primary Outcomes (2)
Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure.
Dual primary efficacy Primary endpoint analysed in all patients randomised (Full analysis set). The analysis was assessed on Full Analysis Set, including events occurring on or prior to Primary Analysis Censoring Date.
Up to 42.1 months
Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure for LVEF <60% Subpopulation
Dual primary efficacy Primary endpoint analysed in all patients randomised with LVEF \< 60% at baseline. The analysis was assessed on Full Analysis Set, including events occurring on or prior to Primary Analysis Censoring Date.
Up to 42.1 months
Secondary Outcomes (5)
Events Included in the Composite Endpoint of CV Death or Recurrent Heart Failure Event (Hospitalization Due to Heart Failure or Urgent Heart Failure Visit)
Up to 42.1 months
Events Included in the Composite Endpoint of CV Death or Recurrent Heart Failure Event (Hospitalization Due to Heart Failure or Urgent Heart Failure Visit) for LVEF <60% Subpopulation
Up to 42.1 months
Change From Baseline in the KCCQ Total Symptom Score at 8 Months
Baseline and 8 months or death before 8 months
Subjects Included in the Endpoint of Cardiovascular Death
Up to 42.1 months
Subjects Included in the Endpoint of All-cause Mortality
Up to 42.1 months
Study Arms (2)
Dapagliflozin
EXPERIMENTALPatients will be randomized 1:1 to either dapagliflozin or placebo.
Placebo
PLACEBO COMPARATORPlacebo matching dapagliflozin.
Interventions
10 mg tablets given once daily, per oral use.
Eligibility Criteria
You may qualify if:
- Provision of signed informed consent prior to any study specific procedures.
- Male or female patients age ≥40 years.
- Documented diagnosis of symptomatic heart failure (NYHA class II-IV) at enrolment, and a medical history of typical symptoms/signs of heart failure ≥6 weeks before enrolment with at least intermittent need for diuretic treatment.
- Elevated NT-pro BNP levels.
- Both ambulatory and hospitalised patients may be enrolled and randomised. Patients currently hospitalised for HF, must be off intravenous HF medications for at least 24 before randomisation.
You may not qualify if:
- Receiving therapy with an SGLT2 inhibitor within 4 weeks prior to randomisation or previous intolerance to an SGLT2 inhibitor.
- Type 1 diabetes mellitus (T1D).
- eGFR \<25 mL/min/1.73 m2 (CKD-EPI formula) at Visit 1.
- Systolic blood pressure (BP) \<95 mmHg on 2 consecutive measurements at 5-minute intervals, at Visit 1 or at Visit 2.
- Systolic BP≥160 mmHg if not on treatment with ≥3 blood pressure lowering medications or ≥180 mmHg irrespective of treatments, on 2 consecutive measurements at 5-minute intervals, at Visit 1 or at Visit 2.
- MI, unstable angina, coronary revascularization (percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)), ablation of atrial flutter/fibrillation, valve repair/replacement within 12 weeks prior to enrolment. Before enrolment, these patients must have their qualifying echocardiography and/or cardiac MRI examination at least 12 weeks after the event.
- Planned coronary revascularization, ablation of atrial flutter/fibrillation and valve repair/replacement.
- Stroke or transient ischemic attack (TIA) within 12 weeks prior to enrolment.
- Probable alternative or concomitant diagnoses which in the opinion of the investigator could account for the patient's HF symptoms and signs (e.g. anaemia, hypothyroidism).
- Body mass index \>50 kg/m2.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (348)
Research Site
Fairhope, Alabama, 36532, United States
Research Site
Mobile, Alabama, 36608, United States
Research Site
Sheffield, Alabama, 35660, United States
Research Site
Tucson, Arizona, 85724, United States
Research Site
Little Rock, Arkansas, 72204, United States
Research Site
Beverly Hills, California, 90211, United States
Research Site
Loma Linda, California, 92357, United States
Research Site
Los Angeles, California, 90073, United States
Research Site
Stamford, Connecticut, 06905, United States
Research Site
Clearwater, Florida, 33756, United States
Research Site
Miami, Florida, 33155, United States
Research Site
Naples, Florida, 34102, United States
Research Site
Ocala, Florida, 34471, United States
Research Site
Ormond Beach, Florida, 32174, United States
Research Site
Port Charlotte, Florida, 33952, United States
Research Site
Saint Augustine, Florida, 32086, United States
Research Site
Atlanta, Georgia, 30303, United States
Research Site
Chicago, Illinois, 60612, United States
Research Site
Chicago, Illinois, 60637, United States
Research Site
Gurnee, Illinois, 60031, United States
Research Site
Anderson, Indiana, 46011, United States
Research Site
Munster, Indiana, 46321, United States
Research Site
Louisville, Kentucky, 40202, United States
Research Site
Hammond, Louisiana, 70403, United States
Research Site
Houma, Louisiana, 70360, United States
Research Site
Monroe, Louisiana, 71201, United States
Research Site
Boston, Massachusetts, 02114, United States
Research Site
Boston, Massachusetts, 02115, United States
Research Site
Bay City, Michigan, 48708, United States
Research Site
Flint, Michigan, 48504, United States
Research Site
Flint, Michigan, 48532, United States
Research Site
Minneapolis, Minnesota, 55417, United States
Research Site
Rochester, Minnesota, 55905, United States
Research Site
Saint Paul, Minnesota, 55102, United States
Research Site
Kansas City, Missouri, 64111, United States
Research Site
Kansas City, Missouri, 64128, United States
Research Site
St Louis, Missouri, 63136, United States
Research Site
Great Falls, Montana, 59405, United States
Research Site
Las Vegas, Nevada, 89106, United States
Research Site
Lebanon, New Hampshire, 03756, United States
Research Site
Bridgewater, New Jersey, 08807, United States
Research Site
Buffalo, New York, 14215, United States
Research Site
New York, New York, 10001, United States
Research Site
New York, New York, 10021, United States
Research Site
New York, New York, 10029, United States
Research Site
Charlotte, North Carolina, 28277, United States
Research Site
Greensboro, North Carolina, 27405, United States
Research Site
Wilmington, North Carolina, 28401, United States
Research Site
Oklahoma City, Oklahoma, 73134, United States
Research Site
Altoona, Pennsylvania, 16601, United States
Research Site
Doylestown, Pennsylvania, 18901, United States
Research Site
Providence, Rhode Island, 02908, United States
Research Site
Charleston, South Carolina, 29425, United States
Research Site
Rapid City, South Dakota, 57701, United States
Research Site
Jackson, Tennessee, 38301, United States
Research Site
Nashville, Tennessee, 37212, United States
Research Site
Tullahoma, Tennessee, 37388, United States
Research Site
Beaumont, Texas, 77701, United States
Research Site
Humble, Texas, 77338, United States
Research Site
Sherman, Texas, 75092, United States
Research Site
Burlington, Vermont, 05401, United States
Research Site
Falls Church, Virginia, 22042, United States
Research Site
Leesburg, Virginia, 20176, United States
Research Site
Morgantown, West Virginia, 26506, United States
Research Site
Madison, Wisconsin, 53705, United States
Research Site
Milwaukee, Wisconsin, 53295, United States
Research Site
Buenos Aires, C1426ABP, Argentina
Research Site
CABA, 1426, Argentina
Research Site
CABA, C1119ACN, Argentina
Research Site
CABA, C1120AAC, Argentina
Research Site
CABA, C1425AGC, Argentina
Research Site
Catamarca, K4700, Argentina
Research Site
Ciudad Autonoma de Buenos Aire, C1407GTN, Argentina
Research Site
Corrientes, W3400AMZ, Argentina
Research Site
Córdoba, 5003, Argentina
Research Site
Córdoba, X5000AAW, Argentina
Research Site
Córdoba, X5003DCP, Argentina
Research Site
Córdoba, X5004BAL, Argentina
Research Site
Córdoba, X5006CBI, Argentina
Research Site
Mar del Plata, 7600, Argentina
Research Site
Ramos Mejía, B1704ETD, Argentina
Research Site
Rosario, 2000, Argentina
Research Site
San Miguel de Tucumán, 4000, Argentina
Research Site
San Nicolás, B2900DMH, Argentina
Research Site
Santa Fe, S3000FWO, Argentina
Research Site
Aalst, 9300, Belgium
Research Site
Brasschaat, 2930, Belgium
Research Site
Brussels, 1200, Belgium
Research Site
Huy, 4500, Belgium
Research Site
Kortrijk, 8500, Belgium
Research Site
Leuven, 3000, Belgium
Research Site
Belo Horizonte, 30150-240, Brazil
Research Site
Belo Horizonte, 30210-090, Brazil
Research Site
Blumenau, 89020-430, Brazil
Research Site
Campina Grande do Sul, 83430000, Brazil
Research Site
Campinas, 13010-001, Brazil
Research Site
Campinas, 13060-080, Brazil
Research Site
Curitiba, 80230-130, Brazil
Research Site
Porto Alegre, 90020090, Brazil
Research Site
Porto Alegre, 90035-903, Brazil
Research Site
Rio de Janeiro, 20241-180, Brazil
Research Site
Santo André, 09080-110, Brazil
Research Site
São Paulo, 01141-020, Brazil
Research Site
Votuporanga, 15500-003, Brazil
Research Site
Dimitrovgrad, 6400, Bulgaria
Research Site
Haskovo, Bulgaria
Research Site
Kozloduy, 3320, Bulgaria
Research Site
Pazardzhik, 4400, Bulgaria
Research Site
Pleven, 5800, Bulgaria
Research Site
Plovdiv, 4004, Bulgaria
Research Site
Sofia, 1309, Bulgaria
Research Site
Sofia, 1431, Bulgaria
Research Site
Sofia, 1463, Bulgaria
Research Site
Sofia, 1606, Bulgaria
Research Site
Sofia, 1700, Bulgaria
Research Site
Sofia, 1784, Bulgaria
Research Site
Stara Zagora, 6000, Bulgaria
Research Site
Winnipeg, Manitoba, R2H 2A6, Canada
Research Site
Brampton, Ontario, L6W 2X7, Canada
Research Site
Brampton, Ontario, L6Z 4N5, Canada
Research Site
Burlington, Ontario, L7M 4Y1, Canada
Research Site
Cambridge, Ontario, N1R 6V6, Canada
Research Site
Hamilton, Ontario, L8L 2X2, Canada
Research Site
Newmarket, Ontario, L3Y 2P6, Canada
Research Site
North York, Ontario, M6B 3H7, Canada
Research Site
Oshawa, Ontario, L1J 2K1, Canada
Research Site
Port Perry, Ontario, L9L 1L1, Canada
Research Site
Scarborough Village, Ontario, M1B 4Z8, Canada
Research Site
Toronto, Ontario, M3N 1N1, Canada
Research Site
Toronto, Ontario, M5B 1W8, Canada
Research Site
Toronto, Ontario, M6G 1M2, Canada
Research Site
Toronto, Ontario, M6N 1B5, Canada
Research Site
Waterloo, Ontario, N2T 0C1, Canada
Research Site
York, Ontario, M9N 1W4, Canada
Research Site
Laval, Quebec, H7M 3L9, Canada
Research Site
Montreal, Quebec, H1T 1C8, Canada
Research Site
Saint-Jérôme, Quebec, J7Z 5T3, Canada
Research Site
Terrebonne, Quebec, J6V 2H2, Canada
Research Site
Trois-Rivières, Quebec, G8Z 3R9, Canada
Research Site
Baotou, 014010, China
Research Site
Beijing, 100029, China
Research Site
Beijing, 100049, China
Research Site
Beijing, 100853, China
Research Site
Cangzhou, 061001, China
Research Site
Changchun, 130021, China
Research Site
Changchun, 130033, China
Research Site
Chengdu, 610041, China
Research Site
Chifeng, 024000, China
Research Site
Dalian, 116011, China
Research Site
Daqing, 163000, China
Research Site
Fuzhou, 350025, China
Research Site
Fuzhou, 350031, China
Research Site
Guangzhou, 510100, China
Research Site
Guangzhou, 510120, China
Research Site
Haerbin, 150001, China
Research Site
Jinan, 250013, China
Research Site
Lanzhou, 730030, China
Research Site
Nanchang, 330006, China
Research Site
Nanjing, 2100008, China
Research Site
Nanjing, 210009, China
Research Site
Nanjing, 210011, China
Research Site
Pingxiang, 337055, China
Research Site
Shanghai, 200025, China
Research Site
Shanghai, 200062, China
Research Site
Shanghai, 200090, China
Research Site
Shenyang, 110015, China
Research Site
Tianjin, 300000, China
Research Site
Tianjin, 300142, China
Research Site
Tianjin, 300211, China
Research Site
Tianjin, 300457, China
Research Site
Wuhan, 430000, China
Research Site
Wuhan, 430033, China
Research Site
Xi'an, 710061, China
Research Site
Yinchuan, 750004, China
Research Site
Benešov, 256 01, Czechia
Research Site
Brandýs nad Labem, 250 01, Czechia
Research Site
Brno, 612 00, Czechia
Research Site
Jaroměř, 551 01, Czechia
Research Site
Kladno, 272 80, Czechia
Research Site
Louny, 440 01, Czechia
Research Site
Náchod, 547 01, Czechia
Research Site
Ostrava-Dubina, 700 30, Czechia
Research Site
Pardubice, 532 03, Czechia
Research Site
Prague, 12808, Czechia
Research Site
Příbram, 261 01, Czechia
Research Site
Budapest, 1122, Hungary
Research Site
Budapest, 1139, Hungary
Research Site
Budapest, 1171, Hungary
Research Site
Győr, 9024, Hungary
Research Site
Kecskemét, 6000, Hungary
Research Site
Miskolc, 3529, Hungary
Research Site
Nyíregyháza, 4400, Hungary
Research Site
Szekszárd, 7100, Hungary
Research Site
Szentes, 6600, Hungary
Research Site
Székesfehérvár, 8000, Hungary
Research Site
Szolnok, 5000, Hungary
Research Site
Zalaegerszeg, 8900, Hungary
Research Site
Adachi-ku, 123-0845, Japan
Research Site
Asahi-shi, 289-2511, Japan
Research Site
Azumino-shi, 399-8292, Japan
Research Site
Beppu-shi, 874-0011, Japan
Research Site
Chūōku, 103-0027, Japan
Research Site
Fujisawa-shi, 251-0041, Japan
Research Site
Fujisawa-shi, 251-8550, Japan
Research Site
Funabashi-shi, 274-0065, Japan
Research Site
Hachioji-shi, 192-0918, Japan
Research Site
Hamada-shi, 697-8511, Japan
Research Site
Hamamatsu, 430-0929, Japan
Research Site
Higashiohmi-shi, 527-8505, Japan
Research Site
Ichinomiya-shi, 494-0001, Japan
Research Site
Iizuka-shi, 820-8505, Japan
Research Site
Iwakuni-shi, 740-8510, Japan
Research Site
Kanazawa, 920-8650, Japan
Research Site
Kasugai-shi, 487-0016, Japan
Research Site
Kawasaki-shi, 210-0852, Japan
Research Site
Kishiwada-shi, 596-8522, Japan
Research Site
Kobe, 654-0155, Japan
Research Site
Koga-shi, 306-0041, Japan
Research Site
Kuki-shi, 346-0021, Japan
Research Site
Kure-shi, 737-0023, Japan
Research Site
Kyoto, 612-8555, Japan
Research Site
Matsumoto-shi, 390-8621, Japan
Research Site
Mito, 311-4198, Japan
Research Site
Miura-gun, 240-0116, Japan
Research Site
Nakagami-gun, 901-2393, Japan
Research Site
Nishinomiya-shi, 663-8501, Japan
Research Site
Ōita, 870-0855, Japan
Research Site
Saga, 840-8571, Japan
Research Site
Sagamihara-shi, 252-5188, Japan
Research Site
Sapporo, 063-0005, Japan
Research Site
Shinagawa-ku, 140-8522, Japan
Research Site
Suita-shi, 564-8565, Japan
Research Site
Takamatsu, 760-0018, Japan
Research Site
Takasago-shi, 676-0812, Japan
Research Site
Toride-shi, 302-0022, Japan
Research Site
Tsu, 514-1101, Japan
Research Site
Tsuchiura-shi, 300-0028, Japan
Research Site
Ueda-shi, 386-8610, Japan
Research Site
Ureshino-shi, 843-0393, Japan
Research Site
Utsunomiya, 320-8580, Japan
Research Site
Aguascalientes, 20230, Mexico
Research Site
Culiacán, 80200, Mexico
Research Site
Guadalajara, 44210, Mexico
Research Site
Mazatlán, 82000, Mexico
Research Site
México, 06700, Mexico
Research Site
México, 11650, Mexico
Research Site
Monclova, 25750, Mexico
Research Site
Monterrey, 64020, Mexico
Research Site
Monterrey, 64060, Mexico
Research Site
Querétaro, 76000, Mexico
Research Site
Tijuana, 22150, Mexico
Research Site
Veracruz, 91900, Mexico
Research Site
Veracruz, 91910, Mexico
Research Site
Amsterdam, 1061 AE, Netherlands
Research Site
Arnhem, 6815 AD, Netherlands
Research Site
Dordrecht, 3318 AT, Netherlands
Research Site
Groningen, 9700 RB, Netherlands
Research Site
Heerlen, 6419 PC, Netherlands
Research Site
Leiderdorp, 2353 GA, Netherlands
Research Site
Meppel, 7943 KA, Netherlands
Research Site
Rotterdam, 3083 AN, Netherlands
Research Site
The Hague, 2545 AA, Netherlands
Research Site
Uden, 5406 PT, Netherlands
Research Site
Veldhoven, 5504 DB, Netherlands
Research Site
Bellavista, CALLAO 2, Peru
Research Site
Callao, CALLAO 2, Peru
Research Site
Chancay, 15131, Peru
Research Site
Chorrillos, Lima 9, Peru
Research Site
Lima, 14, Peru
Research Site
Lima, 15088, Peru
Research Site
Lima, L11, Peru
Research Site
Lima, L18, Peru
Research Site
Lima, LIMA 1, Peru
Research Site
Lima, LIMA 31, Peru
Research Site
Lima, LIMA 41, Peru
Research Site
San Isidro, 15073, Peru
Research Site
Urb. El Chipe, 20007, Peru
Research Site
Bialystok, 15-111, Poland
Research Site
Bochnia, 32-700, Poland
Research Site
Chojnice, 89-600, Poland
Research Site
Gdansk, 80-286, Poland
Research Site
Gdynia, 81-157, Poland
Research Site
Gdynia, 81-423, Poland
Research Site
Jasło, 38-200, Poland
Research Site
Katowice, 40-081, Poland
Research Site
Lodz, 92-213, Poland
Research Site
Lublin, 20-044, Poland
Research Site
Opole, 45-056, Poland
Research Site
Oława, 55-200, Poland
Research Site
Płock, 09-402, Poland
Research Site
Rzeszów, 35-055, Poland
Research Site
Torun, 87-100, Poland
Research Site
Wierzchosławice, 33-122, Poland
Research Site
Wroclaw, 50-981, Poland
Research Site
Brasov, 500365, Romania
Research Site
Craiova, 200642, Romania
Research Site
Iași, 700304, Romania
Research Site
Iași, 700400, Romania
Research Site
Iași, 700515, Romania
Research Site
Tg Mures, 540143, Romania
Research Site
Chelyabinsk, 454091, Russia
Research Site
Moscow, 109263, Russia
Research Site
Moscow, 111539, Russia
Research Site
Moscow, 117292, Russia
Research Site
Moscow, 119991, Russia
Research Site
Moscow, 121552, Russia
Research Site
Novosibirsk, 630055, Russia
Research Site
Perm, 614056, Russia
Research Site
Ryazan, 390039, Russia
Research Site
Saint Petersburg, 191015, Russia
Research Site
Saint Petersburg, 194354, Russia
Research Site
Saint Petersburg, 198260, Russia
Research Site
Saint Petersburg, 199226, Russia
Research Site
Tver', 170036, Russia
Research Site
Dammam, 31463, Saudi Arabia
Research Site
Jeddah, 21499, Saudi Arabia
Research Site
Jeddah, 22252, Saudi Arabia
Research Site
Riyadh, 11426, Saudi Arabia
Research Site
Riyadh, 11462, Saudi Arabia
Research Site
Riyadh, 11525, Saudi Arabia
Research Site
A Coruña, 15006, Spain
Research Site
Barcelona, 08003, Spain
Research Site
Hospitalet de Llobregat(Barcel, 08907, Spain
Research Site
Madrid, 28040, Spain
Research Site
Madrid, 28041, Spain
Research Site
Sanlúcar de Barrameda (Cádiz), 11540, Spain
Research Site
Santiago(A Coruña), 15706, Spain
Research Site
Seville, 41071, Spain
Research Site
Valencia, 46010, Spain
Research Site
Valencia, 46026, Spain
Research Site
Villamartín (Cádiz), 11650, Spain
Research Site
Hsinchu, 300, Taiwan
Research Site
Kaohsiung City, 80756, Taiwan
Research Site
Kaohsiung City, 82445, Taiwan
Research Site
Taichung, 40201, Taiwan
Research Site
Taichung, 40705, Taiwan
Research Site
Taichung, Taiwan
Research Site
Tainan, 704, Taiwan
Research Site
Taipei, 110, Taiwan
Research Site
Taipei, 11217, Taiwan
Research Site
Taipei, 11220, Taiwan
Research Site
Taipei, 114, Taiwan
Research Site
Taipei, Taiwan
Research Site
Taoyuan, 333, Taiwan
Research Site
Hanoi, 100000, Vietnam
Research Site
Ho Chi Minh City, 700000, Vietnam
Research Site
Ho Chi Minh City, 70000, Vietnam
Research Site
Ho Chi Minh City, Vietnam
Related Publications (48)
Myte R, Mattsson A, Poole M, Little DJ, Nystrom P, Henderson A, Claggett BL, Gasparyan SB, Solomon SD, McMurray JJV. Survival Odds to Minimize Risk Heterogeneity Bias in Heart Failure Trials: Application to Dapagliflozin. Circ Heart Fail. 2025 Dec;18(12):e013496. doi: 10.1161/CIRCHEARTFAILURE.125.013496. Epub 2025 Oct 31.
PMID: 41170566DERIVEDOstrominski JW, Neuen BL, Claggett BL, Anand IS, Desai AS, Jhund PS, Lam CSP, Pfeffer MA, Pitt B, Zannad F, Zile MR, Packer M, Docherty KF, McMurray JJV, Solomon SD, Vaduganathan M. Natriuretic Peptides, Body Mass Index, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. J Am Coll Cardiol. 2025 Nov 18;86(20):1823-1839. doi: 10.1016/j.jacc.2025.08.028. Epub 2025 Aug 27.
PMID: 40892613DERIVEDSiqueira SRO, Pabon MA, Vaduganathan M, Claggett BL, Lam CSP, Kosiborod MN, de Boer RA, Shah SJ, Fang JC, Desai AS, Jhund PS, Inzucchi SE, Martinez F, Hernandez AF, Petersson M, McMurray JJV, Solomon SD, Vardeny O. Achieved Ejection Fraction and Effects of Dapagliflozin in Heart Failure With Improved Ejection Fraction. JACC Heart Fail. 2025 Oct;13(10):102585. doi: 10.1016/j.jchf.2025.102585. Epub 2025 Aug 19.
PMID: 40834567DERIVEDInciardi RM, Lu H, Claggett BL, Desai AS, Jhund PS, Lam CSP, Kosiborod MN, Inzucchi SE, Martinez FA, de Boer RA, Hernandez AF, Shah SJ, Kober L, Ponikowski P, Sabatine MS, Petersson M, Langkilde AM, McMurray JJV, Vaduganathan M, Solomon SD. Severe Heart Failure and Treatment With Dapagliflozin Across the Ejection Fraction Spectrum: DAPA-HF and DELIVER. JACC Heart Fail. 2025 Apr;13(4):618-627. doi: 10.1016/j.jchf.2024.11.023. Epub 2025 Mar 5.
PMID: 40047763DERIVEDYang M, Kondo T, Talebi A, Jhund PS, Docherty KF, Claggett BL, Vaduganathan M, Bachus E, Hernandez AF, Lam CSP, Martinez FA, de Boer RA, Kosiborod MN, Desai AS, Kober L, Ponikowski P, Sabatine MS, Solomon SD, McMurray JJV. EuroQol 5-Dimension Questionnaire in Heart Failure With Reduced, Mildly Reduced, and Preserved Ejection Fraction: A Patient-Level Analysis of DAPA-HF and DELIVER. JACC Heart Fail. 2025 Feb;13(2):277-292. doi: 10.1016/j.jchf.2024.10.020.
PMID: 39909641DERIVEDLu H, Kondo T, Claggett BL, Vaduganathan M, Neuen BL, Beldhuis IE, Jhund PS, Mc Causland FR, Anand IS, Pfeffer MA, Pitt B, Zannad F, Zile MR, McMurray JJV, Solomon SD, Desai AS. Systolic Blood Pressure and Pulse Pressure in Heart Failure: Pooled Participant-Level Analysis of 4 Trials. J Am Coll Cardiol. 2025 Feb 25;85(7):710-722. doi: 10.1016/j.jacc.2024.11.007. Epub 2024 Nov 15.
PMID: 39745404DERIVEDKondo T, Gasparyan SB, Jhund PS, Bengtsson O, Claggett BL, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Kober L, Lam CSP, Langkilde AM, Martinez FA, Petersson M, Ponikowski P, Sabatine MS, Shah SJ, Sjostrand M, Wilderang U, Vaduganathan M, Solomon SD, McMurray JJV. Use of Win Statistics to Analyze Outcomes in the DAPA-HF and DELIVER Trials. NEJM Evid. 2023 Nov;2(11):EVIDoa2300042. doi: 10.1056/EVIDoa2300042. Epub 2023 Oct 24.
PMID: 38320525DERIVEDVardeny O, Desai AS, Jhund PS, Fang JC, Claggett B, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez FA, Shah SJ, Mc Causland FR, Petrie MC, Vaduganathan M, McMurray JJV, Solomon SD. Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction: A Post Hoc Analysis of the DELIVER Trial. JAMA Cardiol. 2024 Mar 1;9(3):283-289. doi: 10.1001/jamacardio.2023.5318.
PMID: 38265835DERIVEDMc Causland FR, Claggett BL, Vaduganathan M, Desai A, Jhund P, Vardeny O, Fang JC, de Boer RA, Docherty KF, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Saraiva JFK, McGrath MM, Shah SJ, Verma S, Langkilde AM, Petersson M, McMurray JJV, Solomon SD. Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial. JAMA Cardiol. 2024 Feb 1;9(2):144-152. doi: 10.1001/jamacardio.2023.4664.
PMID: 37952176DERIVEDKondo T, Butt JH, Curtain JP, Jhund PS, Docherty KF, Claggett BL, Vaduganathan M, Bachus E, Hernandez AF, Lam CSP, Inzucchi SE, Martinez FA, de Boer RA, Kosiborod MN, Desai AS, Kober L, Ponikowski P, Sabatine MS, Solomon SD, McMurray JJV. Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER. Circ Heart Fail. 2023 Dec;16(12):e010898. doi: 10.1161/CIRCHEARTFAILURE.123.010898. Epub 2023 Oct 27.
PMID: 37886880DERIVEDOstrominski JW, Vaduganathan M, Selvaraj S, Claggett BL, Miao ZM, Desai AS, Jhund PS, Kosiborod MN, Lam CSP, Inzucchi SE, Martinez FA, de Boer RA, Hernandez AF, Shah SJ, Petersson M, Maria Langkilde A, McMurray JJV, Solomon SD. Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial. Circulation. 2023 Dec 12;148(24):1945-1957. doi: 10.1161/CIRCULATIONAHA.123.065254. Epub 2023 Oct 13.
PMID: 37830208DERIVEDBhatt AS, Kosiborod MN, Claggett BL, Miao ZM, Vaduganathan M, Lam CSP, Hernandez AF, Martinez FA, Inzucchi SE, Shah SJ, de Boer RA, Jhund PS, Desai AS, Fang JC, Han Y, Comin-Colet J, Drozdz J, Vardeny O, Merkely B, Lindholm D, Peterson M, Langkilde AM, McMurray JJV, Solomon SD. Impact of COVID-19 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial. Eur J Heart Fail. 2023 Dec;25(12):2177-2188. doi: 10.1002/ejhf.3043. Epub 2023 Oct 9.
PMID: 37771274DERIVEDPeikert A, Bart BA, Vaduganathan M, Claggett BL, Kulac IJ, Kosiborod MN, Desai AS, Jhund PS, Lam CSP, Inzucchi SE, Martinez FA, de Boer RA, Hernandez AF, Shah SJ, Petersson M, Langkilde AM, McMurray JJV, Solomon SD, Vardeny O. Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF: The DELIVER Trial. JACC Heart Fail. 2024 Apr;12(4):631-644. doi: 10.1016/j.jchf.2023.09.007. Epub 2023 Sep 27.
PMID: 37767674DERIVEDChatur S, Vaduganathan M, Claggett BL, Mc Causland FR, Desai AS, Jhund PS, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez FA, Shah SJ, Sabatine MS, Kober L, Ponikowski P, Merkely B, Petersson M, Langkilde AM, McMurray JJV, Solomon SD. Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function. J Am Coll Cardiol. 2023 Nov 7;82(19):1854-1863. doi: 10.1016/j.jacc.2023.08.026. Epub 2023 Aug 25.
PMID: 37634707DERIVEDButt JH, Lu H, Kondo T, Bachus E, de Boer RA, Inzucchi SE, Jhund PS, Kosiborod MN, Lam CSP, Martinez FA, Vaduganathan M, Solomon SD, McMurray JJV. Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: Insights from DELIVER. Eur J Heart Fail. 2023 Nov;25(11):2078-2090. doi: 10.1002/ejhf.3000. Epub 2023 Sep 1.
PMID: 37634087DERIVEDChatur S, Vaduganathan M, Claggett BL, Cunningham JW, Docherty KF, Desai AS, Jhund PS, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez FA, Shah SJ, Petersson M, Langkilde AM, McMurray JJV, Solomon SD. Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial. Circulation. 2023 Nov 28;148(22):1735-1745. doi: 10.1161/CIRCULATIONAHA.123.066506. Epub 2023 Aug 26.
PMID: 37632455DERIVEDPeikert A, Goyal P, Vaduganathan M, Claggett BL, Kulac IJ, Miao ZM, Vardeny O, Kosiborod MN, Desai AS, Jhund PS, Lam CSP, Inzucchi SE, Martinez FA, de Boer RA, Hernandez AF, Shah SJ, Petersson M, Langkilde AM, McMurray JJV, Solomon SD. Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy Status. JACC Heart Fail. 2023 Oct;11(10):1380-1393. doi: 10.1016/j.jchf.2023.05.014. Epub 2023 May 21.
PMID: 37294244DERIVEDOstrominski JW, Thierer J, Claggett BL, Miao ZM, Desai AS, Jhund PS, Kosiborod MN, Lam CSP, Inzucchi SE, Martinez FA, de Boer RA, Hernandez AF, Shah SJ, Petersson M, Langkilde AM, McMurray JJV, Solomon SD, Vaduganathan M. Cardio-Renal-Metabolic Overlap, Outcomes, and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JACC Heart Fail. 2023 Nov;11(11):1491-1503. doi: 10.1016/j.jchf.2023.05.015. Epub 2023 May 24.
PMID: 37226448DERIVEDBhatt AS, Lindholm D, Nilsson A, Zaozerska N, Claggett BL, Vaduganathan M, Kosiborod MN, Lam CSP, Hernandez AF, Martinez FA, Inzucchi SE, Shah SJ, de Boer RA, Desai A, Jhund PS, Langkilde AM, Petersson M, McMurray JJV, Solomon SD. Operational challenges and mitigation measures during the COVID-19 pandemic-Lessons from DELIVER. Am Heart J. 2023 Sep;263:133-140. doi: 10.1016/j.ahj.2023.05.013. Epub 2023 May 21.
PMID: 37220822DERIVEDButt JH, Kondo T, Yang M, Jhund PS, Docherty KF, Vaduganathan M, Claggett BL, Hernandez AF, Lam CSP, Inzucchi SE, Martinez FA, de Boer RA, Kosiborod MN, Desai AS, Kober L, Ponikowski P, Sabatine MS, Shah SJ, Zaozerska N, Wilderang U, Bengtsson O, Solomon SD, McMurray JJV. Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER. Eur Heart J. 2023 Jun 25;44(24):2170-2183. doi: 10.1093/eurheartj/ehad276.
PMID: 37220172DERIVEDChatur S, Vaduganathan M, Claggett B, Vardeny O, Desai AS, Jhund PS, de Boer RA, Lam CSP, Kosiborod MN, Shah SJ, Martinez F, Inzucchi SE, Hernandez AF, Haddad T, Mitter SS, Miao ZM, Petersson M, Maria Langkilde A, McMurray JJV, Solomon SD. Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial. Eur Heart J. 2023 Aug 14;44(31):2930-2943. doi: 10.1093/eurheartj/ehad283.
PMID: 37220093DERIVEDChatur S, Cunningham JW, Vaduganathan M, Mc Causland FR, Claggett BL, Desai AS, Miao ZM, Jhund PS, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez FA, Shah SJ, Petersson M, Langkilde AM, McMurray JJV, Solomon SD. Renal and blood pressure effects of dapagliflozin in recently hospitalized patients with heart failure with mildly reduced or preserved ejection fraction: Insights from the DELIVER trial. Eur J Heart Fail. 2023 Jul;25(7):1170-1175. doi: 10.1002/ejhf.2915. Epub 2023 Jun 8.
PMID: 37212168DERIVEDBhatt AS, Kosiborod MN, Vaduganathan M, Claggett BL, Miao ZM, Kulac IJ, Lam CSP, Hernandez AF, Martinez F, Inzucchi SE, Shah SJ, de Boer RA, Jhund PS, Desai AS, Petersson M, Langkilde AM, McMurray JJV, Solomon SD. Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant-level pooled analysis from the DAPA-HF and DELIVER trials. Eur J Heart Fail. 2023 Jul;25(7):981-988. doi: 10.1002/ejhf.2909. Epub 2023 Jun 7.
PMID: 37211977DERIVEDChatur S, Kondo T, Claggett BL, Docherty K, Miao ZM, Desai AS, Jhund PS, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez FA, Shah SJ, Petersson M, Langkilde AM, McMurray JJV, Solomon SD, Vaduganathan M. Effects of dapagliflozin on heart failure hospitalizations according to severity of inpatient course: Insights from DELIVER and DAPA-HF. Eur J Heart Fail. 2023 Aug;25(8):1364-1371. doi: 10.1002/ejhf.2912. Epub 2023 Jun 8.
PMID: 37210608DERIVEDPeikert A, Chandra A, Kosiborod MN, Claggett BL, Desai AS, Jhund PS, Lam CSP, Inzucchi SE, Martinez FA, de Boer RA, Hernandez AF, Shah SJ, Janssens SP, Belohlavek J, Borleffs CJW, Dobreanu D, Langkilde AM, Bengtsson O, Petersson M, McMurray JJV, Solomon SD, Vaduganathan M. Association of Dapagliflozin vs Placebo With Individual Kansas City Cardiomyopathy Questionnaire Components in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the DELIVER Trial. JAMA Cardiol. 2023 Jul 1;8(7):684-690. doi: 10.1001/jamacardio.2023.1342.
PMID: 37208998DERIVEDJhund PS, Claggett BL, Talebi A, Butt JH, Gasparyan SB, Wei LJ, McCaw ZR, Wilderang U, Bengtsson O, Desai AS, Petersson M, Langkilde AM, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez FA, Shah SJ, Vaduganathan M, Solomon SD, McMurray JJV. Effect of Dapagliflozin on Total Heart Failure Events in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Trial. JAMA Cardiol. 2023 Jun 1;8(6):554-563. doi: 10.1001/jamacardio.2023.0711.
PMID: 37099283DERIVEDVaduganathan M, Claggett BL, Jhund P, Miao ZM, de Boer RA, Lam CSP, Desai AS, Bengsston O, McMurray JJV, Solomon SD. Dapagliflozin and All-Cause Hospitalizations in Patients With Heart Failure With Preserved Ejection Fraction. J Am Coll Cardiol. 2023 Mar 14;81(10):1004-1006. doi: 10.1016/j.jacc.2022.12.026. No abstract available.
PMID: 36889870DERIVEDButt JH, Docherty KF, Claggett BL, Desai AS, Fang JC, Petersson M, Langkilde AM, de Boer RA, Cabrera Honorio JW, Hernandez AF, Inzucchi SE, Kosiborod MN, Kober L, Lam CSP, Martinez FA, Ponikowski P, Sabatine MS, Vardeny O, O'Meara E, Saraiva JFK, Shah SJ, Vaduganathan M, Jhund PS, Solomon SD, McMurray JJV. Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum. JACC Heart Fail. 2023 Apr;11(4):375-388. doi: 10.1016/j.jchf.2022.11.014. Epub 2023 Feb 1.
PMID: 36881399DERIVEDKondo T, Jering KS, Borleffs CJW, de Boer RA, Claggett BL, Desai AS, Dobreanu D, Inzucchi SE, Hernandez AF, Janssens SP, Jhund PS, Kosiborod MN, Lam CSP, Langkilde AM, Martinez FA, Petersson M, Vinh PN, Vaduganathan M, Solomon SD, McMurray JJV. Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER Trial. Circulation. 2023 Apr 4;147(14):1067-1078. doi: 10.1161/CIRCULATIONAHA.122.062918. Epub 2023 Mar 6.
PMID: 36876483DERIVEDButt JH, Docherty KF, Claggett BL, Desai AS, Petersson M, Langkilde AM, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Kober L, Lam CSP, Martinez FA, Ponikowski P, Sabatine MS, Shah SJ, Vaduganathan M, Jhund PS, Solomon SD, McMurray JJV. Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER. JAMA Cardiol. 2023 Apr 1;8(4):386-393. doi: 10.1001/jamacardio.2022.5608.
PMID: 36811901DERIVEDSelvaraj S, Vaduganathan M, Claggett BL, Miao ZM, Fang JC, Vardeny O, Desai AS, Shah SJ, Lam CSP, Martinez FA, Inzucchi SE, de Boer RA, Petersson M, Langkilde AM, McMurray JJV, Solomon SD. Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: DELIVER. JACC Heart Fail. 2023 Jan;11(1):76-89. doi: 10.1016/j.jchf.2022.09.002. Epub 2022 Oct 2.
PMID: 36599553DERIVEDKosiborod MN, Bhatt AS, Claggett BL, Vaduganathan M, Kulac IJ, Lam CSP, Hernandez AF, Martinez FA, Inzucchi SE, Shah SJ, de Boer RA, Jhund PS, Desai AS, Fang JC, Han Y, Comin-Colet J, Vardeny O, Lindholm D, Wilderang U, Bengtsson O, McMurray JJV, Solomon SD. Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection Fraction. J Am Coll Cardiol. 2023 Feb 7;81(5):460-473. doi: 10.1016/j.jacc.2022.11.006. Epub 2022 Dec 14.
PMID: 36526515DERIVEDVardeny O, Fang JC, Desai AS, Jhund PS, Claggett B, Vaduganathan M, de Boer RA, Hernandez AF, Lam CSP, Inzucchi SE, Martinez FA, Kosiborod MN, DeMets D, O'Meara E, Zieroth S, Comin-Colet J, Drozdz J, Chiang CE, Kitakaze M, Petersson M, Lindholm D, Langkilde AM, McMurray JJV, Solomon SD. Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial. Nat Med. 2022 Dec;28(12):2504-2511. doi: 10.1038/s41591-022-02102-9. Epub 2022 Dec 15.
PMID: 36522606DERIVEDInzucchi SE, Claggett BL, Vaduganathan M, Desai AS, Jhund PS, de Boer RA, Hernandez AF, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Verma S, Han Y, Kerr Saraiva JF, Bengtsson O, Petersson M, Langkilde AM, McMurray JJV, Solomon SD. Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2022 Dec;10(12):869-881. doi: 10.1016/S2213-8587(22)00308-4. Epub 2022 Nov 10.
PMID: 36372069DERIVEDMc Causland FR, Claggett BL, Vaduganathan M, Desai AS, Jhund P, de Boer RA, Docherty K, Fang J, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Saraiva JFK, McGrath MM, Shah SJ, Verma S, Langkilde AM, Petersson M, McMurray JJV, Solomon SD. Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Randomized Clinical Trial. JAMA Cardiol. 2023 Jan 1;8(1):56-65. doi: 10.1001/jamacardio.2022.4210.
PMID: 36326604DERIVEDVaduganathan M, Claggett BL, Jhund P, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Hegde SM, Lindholm D, Petersson M, Langkilde AM, McMurray JJV, Solomon SD. Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial. JAMA Cardiol. 2022 Dec 1;7(12):1259-1263. doi: 10.1001/jamacardio.2022.3750.
PMID: 36190011DERIVEDDesai AS, Jhund PS, Claggett BL, Vaduganathan M, Miao ZM, Kondo T, Barkoudah E, Brahimi A, Connolly E, Finn P, Lang NN, Mc Causland FR, McGrath M, Petrie MC, McMurray JJV, Solomon SD. Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction: A Participant-Level Pooled Analysis of DAPA-HF and DELIVER. JAMA Cardiol. 2022 Dec 1;7(12):1227-1234. doi: 10.1001/jamacardio.2022.3736.
PMID: 36189985DERIVEDMyhre PL, Vaduganathan M, Claggett BL, Miao ZM, Jhund PS, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Lindholm D, Petersson M, Langkilde AM, McMurray JJV, Solomon SD. Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JACC Heart Fail. 2022 Dec;10(12):902-913. doi: 10.1016/j.jchf.2022.08.007. Epub 2022 Aug 27.
PMID: 36114137DERIVEDPeters AE, Ogunniyi MO, Hegde SM, Bianco C, Ghafghazi S, Hernandez AF, DeVore AD. A multicenter program for electronic health record screening for patients with heart failure with preserved ejection fraction: Lessons from the DELIVER-EHR initiative. Contemp Clin Trials. 2022 Oct;121:106924. doi: 10.1016/j.cct.2022.106924. Epub 2022 Sep 12.
PMID: 36100197DERIVEDCunningham JW, Vaduganathan M, Claggett BL, Kulac IJ, Desai AS, Jhund PS, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, McGrath MM, O'Meara E, Wilderang U, Lindholm D, Petersson M, Langkilde AM, McMurray JJV, Solomon SD. Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction. J Am Coll Cardiol. 2022 Oct 4;80(14):1302-1310. doi: 10.1016/j.jacc.2022.07.021. Epub 2022 Aug 27.
PMID: 36041912DERIVEDVaduganathan M, Claggett BL, Jhund P, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Lindholm D, Petersson M, Langkilde AM, McMurray JJV, Solomon SD. Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart Failure. J Am Coll Cardiol. 2022 Nov 8;80(19):1775-1784. doi: 10.1016/j.jacc.2022.08.745. Epub 2022 Aug 27.
PMID: 36041669DERIVEDButt JH, Kondo T, Jhund PS, Comin-Colet J, de Boer RA, Desai AS, Hernandez AF, Inzucchi SE, Janssens SP, Kosiborod MN, Lam CSP, Langkilde AM, Lindholm D, Martinez F, Petersson M, Shah SJ, Thierer J, Vaduganathan M, Verma S, Wilderang U, Claggett BC, Solomon SD, McMurray JJV. Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction. J Am Coll Cardiol. 2022 Nov 1;80(18):1705-1717. doi: 10.1016/j.jacc.2022.08.718. Epub 2022 Aug 27.
PMID: 36041668DERIVEDPeikert A, Martinez FA, Vaduganathan M, Claggett BL, Kulac IJ, Desai AS, Jhund PS, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Shah SJ, Katova T, Merkely B, Vardeny O, Wilderang U, Lindholm D, Petersson M, Langkilde AM, McMurray JJV, Solomon SD. Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial. Circ Heart Fail. 2022 Oct;15(10):e010080. doi: 10.1161/CIRCHEARTFAILURE.122.010080. Epub 2022 Aug 27.
PMID: 36029467DERIVEDButt JH, Jhund PS, Belohlavek J, de Boer RA, Chiang CE, Desai AS, Drozdz J, Hernandez AF, Inzucchi SE, Katova T, Kitakaze M, Kosiborod MN, Lam CSP, Maria Langkilde A, Lindholm D, Bachus E, Martinez F, Merkely B, Petersson M, Saraiva JFK, Shah SJ, Vaduganathan M, Vardeny O, Wilderang U, Claggett BL, Solomon SD, McMurray JJV. Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial. Circulation. 2022 Oct 18;146(16):1210-1224. doi: 10.1161/CIRCULATIONAHA.122.061754. Epub 2022 Aug 27.
PMID: 36029465DERIVEDSolomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Jhund PS, Belohlavek J, Chiang CE, Borleffs CJW, Comin-Colet J, Dobreanu D, Drozdz J, Fang JC, Alcocer-Gamba MA, Al Habeeb W, Han Y, Cabrera Honorio JW, Janssens SP, Katova T, Kitakaze M, Merkely B, O'Meara E, Saraiva JFK, Tereshchenko SN, Thierer J, Vaduganathan M, Vardeny O, Verma S, Pham VN, Wilderang U, Zaozerska N, Bachus E, Lindholm D, Petersson M, Langkilde AM; DELIVER Trial Committees and Investigators. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022 Sep 22;387(12):1089-1098. doi: 10.1056/NEJMoa2206286. Epub 2022 Aug 27.
PMID: 36027570DERIVEDSolomon SD, Vaduganathan M, Claggett BL, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Belohlavek J, Chiang CE, Willem Borleffs CJ, Comin-Colet J, Dobreanu D, Drozdz J, Fang JC, Alcocer Gamba MA, Al Habeeb W, Han Y, Cabrera Honorio JW, Janssens SP, Katova T, Kitakaze M, Merkely B, O'Meara E, Kerr Saraiva JF, Tereschenko SN, Thierer J, Vardeny O, Verma S, Vinh PN, Wilderang U, Zaozerska N, Lindholm D, Petersson M, McMurray JJV. Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial. JACC Heart Fail. 2022 Mar;10(3):184-197. doi: 10.1016/j.jchf.2021.11.006.
PMID: 35241246DERIVEDKanie T, Mizuno A, Takaoka Y, Suzuki T, Yoneoka D, Nishikawa Y, Tam WWS, Morze J, Rynkiewicz A, Xin Y, Wu O, Providencia R, Kwong JS. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. Cochrane Database Syst Rev. 2021 Oct 25;10(10):CD013650. doi: 10.1002/14651858.CD013650.pub2.
PMID: 34693515DERIVEDNassif ME, Kosiborod M. Effects of sodium glucose cotransporter type 2 inhibitors on heart failure. Diabetes Obes Metab. 2019 Apr;21 Suppl 2:19-23. doi: 10.1111/dom.13678.
PMID: 31081589DERIVED
Related Links
MeSH Terms
Interventions
Results Point of Contact
- Title
- AstraZeneca Clinical Study Information Center
- Organization
- AstraZeneca AB
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 2, 2018
First Posted
August 7, 2018
Study Start
August 27, 2018
Primary Completion
March 27, 2022
Study Completion
March 27, 2022
Last Updated
July 11, 2023
Results First Posted
July 11, 2023
Record last verified: 2023-07
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP
- Time Frame
- AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
- Access Criteria
- When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.